This article was originally published in Start Up
AlzProtect SAS believes that Alzheimer's disease is caused by the loss of neuroprotective factors including APP intracellular domain and sAPP alpha, both of which are produced during the metabolism of amyloid precursor protein. The start-up is developing compounds that can stimulate the APP, increasing the production of neuroprotective compounds.
You may also be interested in...
Using proprietary assays, Cognition Therapeutics Inc. has discovered small-molecule, highly brain-penetrable drugs that block soluble toxic amyloid beta oligomers in their reactive form, rather than target amyloid beta plaque or expression of the monomer building blocks.
Axerion Therapeutics Inc.'s technology aims to block the binding of Amyloid beta to the prion protein PrP-C, a mechanism its scientists say is the toxic trigger behind neuronal death in Alzheimer's disease. Based at Yale University in New Haven, the team found that mice with AB plaques but no PrP-C showed no cognitive impairment. (Also see "Axerion Therapeutics Inc." - Scrip, 1 Jul, 2010.)
Galantos Pharma GMBH is developing a next-generation version of galantamine, an acetylcholinesterase inhibitor that's been on the market as a cognition enhancer since 2000 and went generic in 2008. Galantos' Memogain is a nasal-formulation galantamine prodrug that it says will permeate the blood-brain barrier more efficiently.